Skip to content

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

Glycogen Storage Disease Type IA

The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    2 and up

Critères de participation

Inclusion Criteria:

* Patient who had:

* DTX401 (full or partial dose) administered in a parent clinical study (Group 1) or
* Prescribed DTX401(full or partial dose) administered in a post-marketing setting (Group 2)
* Patient is willing and able to provide informed consent after the nature of the study has been explained, and prior to any research-related assessments or procedures. If a minor or an adult with cognitive limitations, the patient is willing and able (if possible) to provide assent and have a legally authorized representative provide informed consent after the nature of the study has been explained, and prior to any research-related assessments or procedures.

Exclusion Criteria:

* Presence of any condition that would interfere with study participation, interpretation of results or affect patient's safety in the opinion of the Investigator

Lieu de l'étude

McGill University Health Center
McGill University Health Center
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
Ultragenyx Pharmaceutical Inc
Participants recherchés
Plus d'informations
ID de l'étude: NCT06636383